Tremelimumab is a Monoclonal Antibody owned by AstraZeneca, and is involved in 170 clinical trials, of which 82 were completed, 80 are ongoing, and 8 are planned.
Tremelimumab is directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). The drug candidate binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated down regulation of T-cell activation. Subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.
The revenue for Tremelimumab is expected to reach a total of $3.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tremelimumab NPV Report.
Tremelimumab (Imjudo) human monoclonal antibody against CTLA-4. It is formulated as a solution for intravenous and subcutaneous route of administration. Imjudo is indicated in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma and in combination with durvalumab and platinum-based chemotherapy, is indicated for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor.(EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
Tremelimumab (CP-675206) is under development for the treatment of squamous and non-squamous non-small cell lung cancer, epithelial ovarian, cutaneous melanoma, fallopian tube or primary peritoneal carcinoma, urothelial bladder cancer, poorly differentiated thyroid carcinoma, anaplastic thyroid cancer, follicular thyroid cancer, medullary thyroid cancer and papillary thyroid cancer, renal cell carcinoma, metastatic breast cancer, gastric cancer, adenocarcinoma of the gastroesophageal junction, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast cancer, and HPV negative head and neck squamous cell carcinoma, oral cancer, oropharyngeal cancer, laryngeal cancer, metastatic adenocarcinoma of the pancreas and castrate resistant prostate cancer. The drug candidate is administered intravenously. It is fully human monoclonal antibody targeting human cytotoxic T lymphocyte–associated antigen 4 (CTLA-4, CD152). It was also under development for the treatment of HIV / AIDS, bladder cancer, colorectal cancer, prostate cancer, gastrointestinal tract cancer, metastatic melanoma, unresectable advanced solid tumors and pleural malignant mesothelioma.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.
Quick View – Tremelimumab
|Highest Development Stage|